Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joel, Saltzman"'
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
T-cell infiltration for patient LH-01-26 with BRAF V600 mutation in comparison to study population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8353c4f2e2360c24923a91498af6f545
https://doi.org/10.1158/1078-0432.22482590.v1
https://doi.org/10.1158/1078-0432.22482590.v1
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Multispectral immunofluorescence. Number of cells positive for exhaustion (PD-L1, TIM3, LAG3, CTLA4) and activation markers (OX40) in baseline tumor specimens (A); Quantitation of signals per specimen (B). There are more PDL1 positive tumor cell in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0593ee4c25f03ae86a60bf0b6fbe151b
https://doi.org/10.1158/1078-0432.22482602
https://doi.org/10.1158/1078-0432.22482602
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Consort Diagram.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93254bad61f40c2366abc9d865667816
https://doi.org/10.1158/1078-0432.22482611
https://doi.org/10.1158/1078-0432.22482611
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Intratumoral NK cells (baseline) by change in tumor size (A) and change in CEA (B).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21356901729a3819e64396a350c9cd4c
https://doi.org/10.1158/1078-0432.22482605
https://doi.org/10.1158/1078-0432.22482605
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Correlate of baseline and on-treatment changes in intratumoral immune cells (flow cytometry) with clinical endpoints (Supplementary Table 2A), immune checkpoint expression by multispectral immunofluorescence in tumor microenvironment (Supplementary T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4656dbdd368cd80c10f0a4e81f4b7124
https://doi.org/10.1158/1078-0432.22482593.v1
https://doi.org/10.1158/1078-0432.22482593.v1
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Changes in peripheral blood immune cell populations on treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81b7e7a6c248de7c00e06a35fb026ee2
https://doi.org/10.1158/1078-0432.22482599
https://doi.org/10.1158/1078-0432.22482599
Autor:
Zhenghe Wang, Jennifer R. Eads, Neal J. Meropol, Sanford D. Markowitz, David L. Bajor, Yan Xu, Martina Veigl, Shaveta Vinayak, Smitha S. Krishnamurthi, Joel Saltzman, Jill S. Barnholtz-Sloan, Ronald A. Conlon, Gino Cioffi, Yujun Hao, Janet M. Wang, Zhanwen Du, Shashank Gorityala, J. Eva Selfridge, Yicheng Chen, Xiujing Feng, Yiqing Zhao
Supplementary Figures 1-6 and Tables 1-3. Figure S1. PIK3CA mutant cells are more sensitive to a glutaminase inhibitor CB-839 than their WT counterparts. Figure S2. CB-839 enhances 5-FU tumor inhibitory effect in PIK3CA mutant CRC. Figure S3. Genes a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00979391b3ffe7f859a4ff0835457ca3
https://doi.org/10.1158/0008-5472.22426516.v1
https://doi.org/10.1158/0008-5472.22426516.v1
Autor:
Zhenghe Wang, Jennifer R. Eads, Neal J. Meropol, Sanford D. Markowitz, David L. Bajor, Yan Xu, Martina Veigl, Shaveta Vinayak, Smitha S. Krishnamurthi, Joel Saltzman, Jill S. Barnholtz-Sloan, Ronald A. Conlon, Gino Cioffi, Yujun Hao, Janet M. Wang, Zhanwen Du, Shashank Gorityala, J. Eva Selfridge, Yicheng Chen, Xiujing Feng, Yiqing Zhao
PIK3CA encodes the p110α catalytic subunit of PI3K and is frequently mutated in human cancers, including ∼30% of colorectal cancer. Oncogenic mutations in PIK3CA render colorectal cancers more dependent on glutamine. Here we report that the glutam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3631a7b60d939b8b71154c64bad51452
https://doi.org/10.1158/0008-5472.c.6512362.v1
https://doi.org/10.1158/0008-5472.c.6512362.v1
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Purpose:We evaluated the antitumor efficacy of cetuximab in combination with pembrolizumab in patients with RAS wild-type (RASwt), metastatic colorectal adenocarcinoma (mCRC).Patients and Methods:In this phase Ib/II study, cetuximab was combined with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7a8a05cdbc0efaed4e83711e93b067
https://doi.org/10.1158/1078-0432.c.6530960.v1
https://doi.org/10.1158/1078-0432.c.6530960.v1
Autor:
Patrick M. Boland, Renuka Iyer, Pawel Kalinski, Jennifer A. Jurcevic, Karen A. Hicks, Kristopher Attwood, Alan D. Hutson, Chong Wang, Scott I. Abrams, Jason B. Muhitch, Erik S. Knudsen, Hanna R. Rosenheck, Ram Nambiar, Hans Minderman, Orla Maguire, Agnieszka K. Witkiewicz, Joel Saltzman, Sarbajit Mukherjee, David L. Bajor, Christos Fountzilas
Adverse events with maximum grade seen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e07fca5eaaff4470732460e0b3e54d6
https://doi.org/10.1158/1078-0432.22482596
https://doi.org/10.1158/1078-0432.22482596